Xencor (XNCR) Capital Expenditures (2013 - 2026)
Xencor (XNCR) reported Capital Expenditures of $610000.0 for Q1 2026, down 57.76% year-over-year from $1.4 million in Q1 2025, and down 46.49% quarter-over-quarter from $1.1 million in Q4 2025.
Xencor (XNCR) Capital Expenditures (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Capital Expenditures data on file, last reported at $610000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $610000.0, down 57.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (down 68.74% YoY), and the FY2025 annual result was $3.2 million, down 48.34% from the prior year.
- Capital Expenditures slipped to $610000.0 in Q1 2026 per XNCR's latest filing, from $1.1 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $14.1 million in Q3 2022 and troughed at $132000.0 in Q1 2024.
- A 5-year average of $3.9 million and a median of $1.7 million in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 98.78% in 2024, then jumped 993.94% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $10.0 million in 2022, then tumbled by 90.17% to $980000.0 in 2023, then jumped by 69.8% to $1.7 million in 2024, then slumped by 31.49% to $1.1 million in 2025, then tumbled by 46.49% to $610000.0 in 2026.
- Business Quant data shows XNCR's Capital Expenditures at $610000.0 in Q1 2026, $1.1 million in Q4 2025, and $183000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 610,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 610,000.00 |
| Mar 31, 2026 | 610,000.00 |
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 183,000.00 |
| Sep 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Dec 31, 2023 | 980,000.00 |
| Dec 31, 2023 | 980,000.00 |